MA40761B1 - Utilisation de panels de gènes mutants du fgfr dans l'identification de patients atteints de cancer qui seront sensibles à un traitement avec un inhibiteur du fgfr - Google Patents
Utilisation de panels de gènes mutants du fgfr dans l'identification de patients atteints de cancer qui seront sensibles à un traitement avec un inhibiteur du fgfrInfo
- Publication number
- MA40761B1 MA40761B1 MA40761A MA40761A MA40761B1 MA 40761 B1 MA40761 B1 MA 40761B1 MA 40761 A MA40761 A MA 40761A MA 40761 A MA40761 A MA 40761A MA 40761 B1 MA40761 B1 MA 40761B1
- Authority
- MA
- Morocco
- Prior art keywords
- fgfr
- responsive
- treatment
- cancer patients
- mutant gene
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2531/00—Reactions of nucleic acids characterised by
- C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
- C12Q2531/113—PCR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Cette invention concerne des méthodes d'identification d'un patient atteint de cancer qui sera sensible au traitement avec un inhibiteur du récepteur du facteur de croissance des fibroblastes (fgfr) et des méthodes destinées à traiter des patients atteints de cancer. Les méthodes impliquent l'évaluation d'un échantillon biologique provenant du patient pour identifier la présence d'un ou de plusieurs mutants du fgfr à partir d'un panel de gènes mutants du fgfr. Des kits et des amorces pour identifier la présence d'un ou de plusieurs gènes mutants du fgfr dans un échantillon biologique sont également décrits.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462056159P | 2014-09-26 | 2014-09-26 | |
| PCT/US2015/050996 WO2016048833A2 (fr) | 2014-09-26 | 2015-09-18 | Utilisation de panels de gènes mutants du fgfr dans l'identification de patients atteints de cancer qui seront sensibles à un traitement avec un inhibiteur du fgfr |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA40761A MA40761A (fr) | 2017-08-01 |
| MA40761B1 true MA40761B1 (fr) | 2022-04-29 |
Family
ID=54337343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA40761A MA40761B1 (fr) | 2014-09-26 | 2015-09-18 | Utilisation de panels de gènes mutants du fgfr dans l'identification de patients atteints de cancer qui seront sensibles à un traitement avec un inhibiteur du fgfr |
Country Status (38)
| Country | Link |
|---|---|
| US (3) | US20160090633A1 (fr) |
| EP (2) | EP4063516A1 (fr) |
| JP (4) | JP6766037B2 (fr) |
| KR (3) | KR102839867B1 (fr) |
| CN (2) | CN113957146A (fr) |
| AR (1) | AR102345A1 (fr) |
| AU (3) | AU2015321626B2 (fr) |
| CA (1) | CA2962075C (fr) |
| CO (1) | CO2017003528A2 (fr) |
| CR (1) | CR20170104A (fr) |
| CY (1) | CY1125190T1 (fr) |
| DK (1) | DK3198033T3 (fr) |
| EA (1) | EA037920B1 (fr) |
| EC (1) | ECSP17025787A (fr) |
| ES (1) | ES2912567T3 (fr) |
| GT (1) | GT201700059A (fr) |
| HR (1) | HRP20220496T1 (fr) |
| HU (1) | HUE058219T2 (fr) |
| IL (3) | IL251264B (fr) |
| JO (1) | JO3681B1 (fr) |
| LT (1) | LT3198033T (fr) |
| MA (1) | MA40761B1 (fr) |
| MX (2) | MX392774B (fr) |
| MY (1) | MY194567A (fr) |
| NI (1) | NI201700035A (fr) |
| PH (1) | PH12017500556A1 (fr) |
| PL (1) | PL3198033T3 (fr) |
| PT (1) | PT3198033T (fr) |
| RS (1) | RS63178B1 (fr) |
| SG (1) | SG11201702381QA (fr) |
| SI (1) | SI3198033T1 (fr) |
| SM (1) | SMT202200177T1 (fr) |
| SV (1) | SV2017005415A (fr) |
| TW (1) | TWI706136B (fr) |
| UA (1) | UA122564C2 (fr) |
| UY (1) | UY36325A (fr) |
| WO (1) | WO2016048833A2 (fr) |
| ZA (1) | ZA201702899B (fr) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2643571T3 (es) | 2012-09-27 | 2017-11-23 | Chugai Seiyaku Kabushiki Kaisha | Gen de fusión FGFR3 y fármaco que se dirige al mismo |
| JP6731254B2 (ja) | 2014-01-24 | 2020-07-29 | 公益財団法人がん研究会 | 新規融合体及びその検出法 |
| RU2715236C2 (ru) | 2014-03-26 | 2020-02-26 | Астекс Терапьютикс Лтд | Комбинации |
| KR102839867B1 (ko) | 2014-09-26 | 2025-07-28 | 얀센 파마슈티카 엔브이 | Fgfr 억제제를 사용한 치료에 반응할 암 환자를 확인하는 데 있어서 fgfr 돌연변이 유전자 패널의 사용 |
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| KR20250007056A (ko) * | 2016-03-04 | 2025-01-13 | 다이호야쿠힌고교 가부시키가이샤 | 악성 종양 치료용 제제 및 조성물 |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| JOP20190280A1 (ar) | 2017-06-02 | 2019-12-02 | Janssen Pharmaceutica Nv | مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية |
| EP4130749A1 (fr) | 2018-07-27 | 2023-02-08 | Zepto Life Technology, LLC | Système et procédé de préparation d'échantillons dans la détection de biomarqueurs basée sur gmr |
| JP7761485B2 (ja) * | 2018-09-21 | 2025-10-28 | ヤンセン ファーマシューティカ エヌ．ベー． | 胆管癌の処置 |
| PH12021551949A1 (en) * | 2019-02-12 | 2022-07-18 | Janssen Pharmaceutica Nv | Cancer treatment |
| WO2020201138A1 (fr) | 2019-03-29 | 2020-10-08 | Janssen Pharmaceutica Nv | Inhibiteurs de la tyrosine kinase fgfr pour le traitement du carcinome urothélial |
| CA3130460A1 (fr) | 2019-03-29 | 2020-10-08 | Anne Elizabeth O'HAGAN | Inhibiteurs de tyrosine kinase fgfr pour le traitement du carcinome urothelial |
| MX2021014524A (es) * | 2019-05-31 | 2022-05-19 | Qed Therapeutics Inc | Metodos para tratar canceres del sistema urinario. |
| CN110241183B (zh) * | 2019-06-13 | 2022-10-28 | 南京世和基因生物技术股份有限公司 | 一种fgfr融合基因的检测方法、试剂盒以及探针库 |
| CN114341187A (zh) * | 2019-07-12 | 2022-04-12 | 中外制药株式会社 | 抗突变型fgfr3抗体及其用途 |
| WO2021050100A1 (fr) * | 2019-09-09 | 2021-03-18 | Zepto Life Technology, LLC | Systèmes et procédés de détection de variation génétique dans des acides nucléiques améliorée |
| EP4034118A1 (fr) | 2019-09-26 | 2022-08-03 | Janssen Pharmaceutica NV | Utilisation d'inhibiteurs de fgfr dans des cancers génétiquement modifiés par fgfr pour améliorer la réponse du patient à des inhibiteurs du point de contrôle immunitaire dans des conditions de traitement séquentiel |
| TWI900527B (zh) | 2020-02-12 | 2025-10-11 | 比利時商健生藥品公司 | 用於治療尿路上皮癌的ｆｇｆｒ酪胺酸激酶抑制劑和抗ｐｄ１藥劑 |
| BR112022015827A2 (pt) | 2020-02-12 | 2022-10-04 | Janssen Pharmaceutica Nv | Inibidores de tirosina quinase de fgfr para o tratamento de câncer de bexiga invasivo não muscular de alto risco |
| BR112022020846A2 (pt) * | 2020-04-15 | 2022-12-27 | Alkermes Pharma Ireland Ltd | Agentes imunoestimuladores em combinação com inibidores de angiogênese |
| CN111440790A (zh) * | 2020-05-08 | 2020-07-24 | 公安部物证鉴定中心 | 唾液斑迹dna和rna同时提取的方法 |
| CA3191538A1 (fr) | 2020-09-14 | 2022-03-17 | Ademi Elena SANTIAGO-WALKER | Therapies combinees d'inhibiteurs de fgfr |
| CN112143815B (zh) * | 2020-11-25 | 2021-02-26 | 江苏申基生物科技有限公司 | 一种用于检测人fgfr2基因融合突变的核酸组合物、试剂盒及检测方法 |
| BR112023023935A2 (pt) | 2021-05-19 | 2024-01-30 | Janssen Pharmaceutica Nv | Inibidores de tirosina quinase de fgfr para o tratamento de tumores sólidos avançados |
| JP2024538993A (ja) | 2021-10-12 | 2024-10-28 | タリス バイオメディカル エルエルシー | エルダフィチニブ製剤及び膀胱内投与のためのシステム |
| JP2025507590A (ja) | 2022-02-18 | 2025-03-21 | タリス バイオメディカル エルエルシー | エルダフィチニブ製剤及び膀胱内投与のための浸透圧システム |
| WO2024173377A1 (fr) | 2023-02-13 | 2024-08-22 | Taris Biomedical Llc | Erdafitinib pour administration intravésicale destiné à être utilisé dans le traitement du cancer de la vessie |
| CN120813357A (zh) | 2023-02-13 | 2025-10-17 | 詹森药业有限公司 | 用于治疗高风险非肌层浸润性膀胱癌的fgfr酪氨酸激酶抑制剂 |
| WO2024173716A1 (fr) | 2023-02-17 | 2024-08-22 | Taris Biomedical Llc | Erdafitinib pour administration intravésicale destiné à être utilisé dans le traitement du cancer de la vessie |
| WO2025059602A1 (fr) | 2023-09-14 | 2025-03-20 | Taris Biomedical Llc | Méthodes de traitement du cancer de la vessie à l'aide d'une administration intravésicale d'erdafitinib |
| CN119219611B (zh) * | 2024-12-03 | 2025-04-18 | 南京诺源医疗器械有限公司 | 用于主动靶向成纤维细胞生长因子受体的近红外荧光探针及其制备方法与应用 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000068424A2 (fr) | 1999-05-05 | 2000-11-16 | Institut Curie | Moyens de detection et de traitement des pathologies associees au fgfr3 |
| US7135311B1 (en) | 1999-05-05 | 2006-11-14 | Institut Curie | Means for detecting and treating pathologies linked to FGFR3 |
| JP4649331B2 (ja) | 2002-10-01 | 2011-03-09 | エピゲノミクス アーゲー | 乳房細胞増殖障害の改良治療方法および核酸 |
| DE602004022266D1 (de) * | 2003-03-26 | 2009-09-10 | Progenika Biopharma Sa | Lkarzinoms der blase |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| EP1659175A1 (fr) * | 2004-11-18 | 2006-05-24 | Institut Curie | Altérations des kératoses séborrhéiques et applications dérivées |
| BRPI0611375A2 (pt) | 2005-05-23 | 2010-08-31 | Novartis Ag | formas cristalinas e outras de sais de ácido láctico de 4-amino-5-flúor-3-[6-(4-metilpiperazin-1-il)-1h-benzimid azol-2-il]-1h-quinolin-2-ona |
| WO2007061127A1 (fr) * | 2005-11-22 | 2007-05-31 | Eisai R & D Management Co., Ltd. | Agent antitumeur pour myelomes multiples |
| BRPI0619548A2 (pt) * | 2005-12-08 | 2011-10-04 | Novartis Ag | efeitos inibidores de fgfr3 em transcrição de gene |
| EP1918376A1 (fr) * | 2006-11-03 | 2008-05-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | FGFR4 favorise la résistance des cellules cancéreuses en réponse aux agents chimiothérapeutiques |
| AU2008220821B2 (en) | 2007-02-27 | 2012-09-13 | Novartis Ag | A method of identification of cells that show sensitivity to modulation of signaling mediated by a Fibroblast Growth Factor Receptor or a variant thereof |
| WO2008109369A2 (fr) | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Composés d'acide nucléique permettant d'inhiber l'expression de gène tnf et utilisations de ceux-ci |
| US8163923B2 (en) | 2007-03-14 | 2012-04-24 | Advenchen Laboratories, Llc | Spiro substituted compounds as angiogenesis inhibitors |
| CA2691451C (fr) | 2007-06-21 | 2015-03-24 | Sara H. Fan | Instruments et receptacles pour effectuer des procedes |
| US8071338B2 (en) | 2007-08-08 | 2011-12-06 | Roche Molecular Systems, Inc. | Suppression of amplification using an oligonucleotide and a polymerase significantly lacking 5′-3′ nuclease activity |
| WO2013173485A1 (fr) | 2012-05-15 | 2013-11-21 | Predictive Biosciences, Inc. | Détection de cancers de la vessie |
| WO2013173480A1 (fr) | 2012-05-15 | 2013-11-21 | Predictive Biosciences, Inc. | Détection de récurrence de cancer de la vessie |
| GB0718542D0 (en) | 2007-09-22 | 2007-10-31 | Univ Dundee | Targeted modulation of gene expression |
| TWI381848B (zh) | 2008-10-20 | 2013-01-11 | Imclone Llc | 抗纖維母細胞生長因子受體-3 (fgfr-3) 抗體及包含其之醫藥組合物 |
| JP2012521768A (ja) | 2009-03-27 | 2012-09-20 | ジモジェネティクス・インコーポレイテッド | 抗体−受容体の組み合わせを含む多特異的結合性タンパク質を用いるための組成物および方法 |
| WO2011027219A1 (fr) | 2009-09-04 | 2011-03-10 | Progenika Biopharma, S.A. | Détection à rendement élevé de petites délétions et insertions génomiques |
| US9140689B2 (en) * | 2010-03-14 | 2015-09-22 | Translational Genomics Research Institute | Methods of determining susceptibility of tumors to tyrosine kinase inhibitors |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| GB201020179D0 (en) * | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| CN102293770A (zh) * | 2011-05-25 | 2011-12-28 | 温州医学院 | 新型成纤维细胞生长因子受体酪氨酸激酶抑制剂 |
| CN102319224B (zh) * | 2011-07-27 | 2013-03-20 | 赛乐医药科技(上海)有限公司 | 复方甲氧那明的速释－缓释渗透泵制剂 |
| CN103906848B (zh) | 2011-08-18 | 2016-03-02 | 雀巢产品技术援助有限公司 | 用于检测等位变体的组合物和方法 |
| US20130096021A1 (en) | 2011-09-27 | 2013-04-18 | Arul M. Chinnaiyan | Recurrent gene fusions in breast cancer |
| AR088941A1 (es) | 2011-11-23 | 2014-07-16 | Bayer Ip Gmbh | Anticuerpos anti-fgfr2 y sus usos |
| WO2013088191A1 (fr) * | 2011-12-12 | 2013-06-20 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Antagoniste du récepteur 3 du facteur de croissance des fibroblastes (fgfr3) à utiliser dans le traitement ou la prévention de troubles squelettiques liés à une activation anormale du fgfr3 |
| JP5343177B1 (ja) * | 2012-02-28 | 2013-11-13 | アステラス製薬株式会社 | 含窒素芳香族へテロ環化合物 |
| HK1205528A1 (en) | 2012-03-08 | 2015-12-18 | Astellas Pharma Inc. | Novel fgfr3 fusion product |
| US9254288B2 (en) * | 2012-05-07 | 2016-02-09 | The Translational Genomics Research Institute | Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof |
| GB201209609D0 (en) * | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| EP2871236A4 (fr) * | 2012-07-05 | 2016-03-09 | Nat Cancer Ct | Gène fgfr2 hybride |
| KR102132149B1 (ko) * | 2012-07-24 | 2020-07-09 | 더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 | 융합 단백질 및 그의 방법 |
| RU2015102194A (ru) * | 2012-07-27 | 2016-09-20 | Дженентек, Инк. | Способы лечения связанных с fgfr3 состояний |
| ES2643571T3 (es) * | 2012-09-27 | 2017-11-23 | Chugai Seiyaku Kabushiki Kaisha | Gen de fusión FGFR3 y fármaco que se dirige al mismo |
| CA2890346A1 (fr) * | 2012-11-05 | 2014-05-08 | Foundation Medicine, Inc. | Nouvelles molecules de fusion et leurs utilisations |
| EP3939614A1 (fr) * | 2013-01-18 | 2022-01-19 | Foundation Medicine, Inc. | Méthodes de traitement du cholangiocarcinome |
| US9777333B2 (en) | 2013-04-05 | 2017-10-03 | Life Technologies Corporation | Gene fusion |
| US20160186269A1 (en) | 2013-05-27 | 2016-06-30 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Novel translocations in lung cancer |
| US9783853B2 (en) | 2013-07-12 | 2017-10-10 | The Regents Of The University Of Michigan | Recurrent gene fusions in cancer |
| US20200208224A1 (en) | 2014-09-26 | 2020-07-02 | Janssen Pharmaceutica Nv | Use Of FGFR Mutant Gene Panels In Identifying Cancer Patients That Will Be Responsive To Treatment With An FGFR Inhibitor |
| KR102839867B1 (ko) | 2014-09-26 | 2025-07-28 | 얀센 파마슈티카 엔브이 | Fgfr 억제제를 사용한 치료에 반응할 암 환자를 확인하는 데 있어서 fgfr 돌연변이 유전자 패널의 사용 |
| JOP20190190A1 (ar) | 2017-02-06 | 2019-08-04 | Janssen Pharmaceutica Nv | معالجة سرطان |
-
2015
- 2015-09-18 KR KR1020227040649A patent/KR102839867B1/ko active Active
- 2015-09-18 SG SG11201702381QA patent/SG11201702381QA/en unknown
- 2015-09-18 CR CR20170104A patent/CR20170104A/es unknown
- 2015-09-18 LT LTEPPCT/US2015/050996T patent/LT3198033T/lt unknown
- 2015-09-18 MA MA40761A patent/MA40761B1/fr unknown
- 2015-09-18 CN CN202111247854.6A patent/CN113957146A/zh active Pending
- 2015-09-18 US US14/858,627 patent/US20160090633A1/en not_active Abandoned
- 2015-09-18 KR KR1020257024958A patent/KR20250119657A/ko active Pending
- 2015-09-18 KR KR1020177010946A patent/KR102470456B1/ko active Active
- 2015-09-18 CN CN201580064601.1A patent/CN107002141B/zh active Active
- 2015-09-18 HU HUE15782109A patent/HUE058219T2/hu unknown
- 2015-09-18 EP EP22156319.0A patent/EP4063516A1/fr active Pending
- 2015-09-18 AU AU2015321626A patent/AU2015321626B2/en active Active
- 2015-09-18 RS RS20220400A patent/RS63178B1/sr unknown
- 2015-09-18 WO PCT/US2015/050996 patent/WO2016048833A2/fr not_active Ceased
- 2015-09-18 SI SI201531836T patent/SI3198033T1/sl unknown
- 2015-09-18 MX MX2017003954A patent/MX392774B/es unknown
- 2015-09-18 MY MYPI2017700955A patent/MY194567A/en unknown
- 2015-09-18 CA CA2962075A patent/CA2962075C/fr active Active
- 2015-09-18 DK DK15782109.1T patent/DK3198033T3/da active
- 2015-09-18 HR HRP20220496TT patent/HRP20220496T1/hr unknown
- 2015-09-18 UA UAA201704090A patent/UA122564C2/uk unknown
- 2015-09-18 PT PT157821091T patent/PT3198033T/pt unknown
- 2015-09-18 EP EP15782109.1A patent/EP3198033B1/fr active Active
- 2015-09-18 SM SM20220177T patent/SMT202200177T1/it unknown
- 2015-09-18 ES ES15782109T patent/ES2912567T3/es active Active
- 2015-09-18 EA EA201790716A patent/EA037920B1/ru unknown
- 2015-09-18 JP JP2017516458A patent/JP6766037B2/ja active Active
- 2015-09-18 PL PL15782109.1T patent/PL3198033T3/pl unknown
- 2015-09-22 JO JOP/2015/0238A patent/JO3681B1/ar active
- 2015-09-24 AR ARP150103070A patent/AR102345A1/es unknown
- 2015-09-24 TW TW104131544A patent/TWI706136B/zh active
- 2015-09-25 UY UY0001036325A patent/UY36325A/es active IP Right Grant
-
2017
- 2017-03-19 IL IL251264A patent/IL251264B/en unknown
- 2017-03-24 GT GT201700059A patent/GT201700059A/es unknown
- 2017-03-24 PH PH12017500556A patent/PH12017500556A1/en unknown
- 2017-03-24 SV SV2017005415A patent/SV2017005415A/es unknown
- 2017-03-24 MX MX2022006536A patent/MX2022006536A/es unknown
- 2017-03-24 NI NI201700035A patent/NI201700035A/es unknown
- 2017-04-12 CO CONC2017/0003528A patent/CO2017003528A2/es unknown
- 2017-04-25 ZA ZA2017/02899A patent/ZA201702899B/en unknown
- 2017-04-26 EC ECIEPI201725787A patent/ECSP17025787A/es unknown
-
2018
- 2018-09-19 US US16/136,201 patent/US12037644B2/en active Active
-
2020
- 2020-03-10 JP JP2020040708A patent/JP7051920B2/ja active Active
-
2021
- 2021-11-30 AU AU2021277633A patent/AU2021277633B2/en active Active
-
2022
- 2022-03-23 IL IL291633A patent/IL291633B1/en unknown
- 2022-03-30 JP JP2022056709A patent/JP7558216B2/ja active Active
- 2022-04-29 CY CY20221100314T patent/CY1125190T1/el unknown
-
2024
- 2024-05-28 US US18/675,538 patent/US20240309463A1/en active Pending
- 2024-05-30 JP JP2024087917A patent/JP2024112991A/ja active Pending
-
2025
- 2025-02-28 AU AU2025201448A patent/AU2025201448A1/en active Pending
- 2025-11-06 IL IL324511A patent/IL324511A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA40761B1 (fr) | Utilisation de panels de gènes mutants du fgfr dans l'identification de patients atteints de cancer qui seront sensibles à un traitement avec un inhibiteur du fgfr | |
| Chouraki et al. | Genetics of Alzheimer’s disease | |
| MX2019010958A (es) | Metodos de tratamiento de tumores. | |
| WO2008088854A3 (fr) | Marqueurs génétiques pour la prédiction de sensibilité à une polythérapie | |
| WO2018007872A9 (fr) | Biomarqueurs d'une affection abdominale inflammatoire | |
| EA201792497A1 (ru) | Антитела к gitr для диагностики злокачественной опухоли | |
| DK2114990T3 (da) | Fremgangsmåde til forudsigelse af NSCLC-patienters respons på behandling med en EGFR-TK-inhibitor | |
| MY204203A (en) | Fgfr2 inhibitors for the treatment of cholangiocarcinoma | |
| WO2008073177A3 (fr) | Profils d'expression génique et protéique associés à l'efficacité thérapeutique de l'irinotécan | |
| MX2025004102A (es) | Metodos de identificacion de pacientes con posibilidad de beneficiarse de un tratamiento con un inhibidor de la telomerasa | |
| WO2016146254A8 (fr) | Agents destinés à être utilisés dans le traitement thérapeutique ou prophylactique de la myopie ou de l'hypermétropie | |
| WO2008147206A3 (fr) | Moyens et procédés permettant de classer des échantillons de patients atteints de sclérose en plaques | |
| EP3935190A4 (fr) | Réactifs, procédés et kits pour identifier des femmes enceintes à risque de trouble(s) du lit placentaire | |
| PL410454A1 (pl) | Sposób identyfikowania odpowiedzi chorego na łuszczycę na leczenie genisteiną molekularny test oraz zastosowanie ekspresji genów do wykrywania in vitro łuszczycy | |
| EA201992112A1 (ru) | Способы лечения опухоли | |
| MA47976B1 (fr) | Anticorps dirigés contre trem2 et leur utilisation | |
| ATE530668T1 (de) | Verfahren und kits zur brustkrebsprognose | |
| Kissell et al. | Enhancing Ministry & Improving Clergy Well-Being: Exploring the impact of Bowen’s Systems Coaching on the Work-Related Psychological Health of Clergy | |
| EA201992876A1 (ru) | Способы определения терапии на основании характеристик отдельных клеток из циркулирующих опухолевых клеток (цок) при метастатическом заболевании | |
| JOP20210052A1 (ar) | علاج سرطان الأوعية الصفراوية | |
| Cantu et al. | P116 Complement component 1q assay lacks sensitivity and trends with de novo donor-specific antibody titers | |
| EA202092966A1 (ru) | Способы улучшения ответа на лечение с помощью антитела к lif у индивидуумов, страдающих от рака | |
| PL415440A1 (pl) | Sposoby identyfikacji jagniąt syntetycznych linii BCP i SCP o przydatnym w hodowli składzie tkankowym tuszy | |
| LT2017526A (lt) | Berlyno mėlynojo pasluoksnio ant titano pagrindo formavimo metodai ir jų taikymas gliukozės biologiniuose jutikliuose | |
| RU2008106529A (ru) | Способ воздействия на психофизиологическое состояние человека |